

# Ontario Public Drug Programs Drug Submission Status

---

Generic Name: pembrolizumab

Brand Name: Keytruda

Strength: 50mg/vial powder for solution for infusion

Manufacturer: Merck Canada Inc.

Indication: For the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.

Rapid Review: Not Requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Status:
First Review: (Initial Submission)	10/06/2015	05/11/2015	EO decision rendered	Funding considered through Cancer Care Ontario's New Drug Funding Program

## Rapid Review:

Details of the Rapid Review process can be found at:

[Rapid Review Process](#)

## Review Status:

- Screening - Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete - Manufacturer did not meet the necessary requirements to allow review to proceed.

- Submission complete & under review - Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed - A recommendation was made by the CED.
- Ontario Steering Committee for Cancer Drugs (OSCCD) review completed-A recommendation was made by the OSCCD.
- Executive Officer (EO) decision rendered.

## Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

[The CED recommendation and the EO decision](#)

Updated: July 6, 2016